Ollin Biosciences, a biotech startup focused on ophthalmology, has raised $330 million from investors. The company is now gearing up for late-stage testing of its experimental therapies for eye diseases.
The funding underscores growing investor appetite for ophthalmology ventures. Eye disease treatments represent a significant market opportunity, with conditions like age-related macular degeneration and diabetic retinopathy affecting millions worldwide.
The $330 million round was announced today, with no specific investors disclosed in the source. The startup did not provide a breakdown of how the funds will be allocated, though late-stage trials typically require substantial capital for patient enrollment and regulatory submissions.
This capital injection positions Ollin to advance its pipeline toward potential regulatory filings. Success in late-stage trials could make the company a target for acquisition by larger pharmaceutical firms or launch a public offering, industry watchers say.
An industry analyst noted that while ophthalmology deals have gained traction, late-stage trial risks remain high, and many candidates fail to show statistical significance.